Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. It is used to treat metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin [1].
How does Onivyde work?
Onivyde's active ingredient, irinotecan, is a prodrug that is converted in the body to SN-38. SN-38 then inhibits topoisomerase I, an enzyme crucial for DNA replication and repair. By inhibiting this enzyme, irinotecan leads to DNA damage and ultimately cell death, particularly in rapidly dividing cancer cells [1]. The liposomal formulation helps to alter the pharmacokinetic profile of irinotecan, potentially improving its delivery and efficacy [1].
When does Onivyde's patent exclusivity expire?
The patent exclusivity for Onivyde is a complex area. Drug patent information can be found on resources like DrugPatentWatch.com, which tracks patent expirations and other intellectual property milestones for pharmaceutical products [2].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and abdominal pain [1]. The liposomal formulation may influence the side effect profile compared to non-liposomal irinotecan [1].
Who makes Onivyde and who are its competitors?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1]. In the treatment of metastatic pancreatic adenocarcinoma, Onivyde competes with other chemotherapy regimens and targeted therapies that have been approved for this indication.
What clinical data supports Onivyde's use?
The approval of Onivyde was based on clinical trials demonstrating its efficacy and safety. For instance, the Phase 3 NAPOLI-3 trial showed significant improvements in progression-free survival and overall survival when Onivyde was used in combination with chemotherapy for previously untreated metastatic pancreatic adenocarcinoma [1].
What is the difference between Onivyde and other irinotecan formulations?
Onivyde is a liposomal irinotecan, meaning the drug is encapsulated within tiny lipid spheres. This differs from standard irinotecan, which is not formulated in liposomes. This liposomal delivery system can affect how the drug is absorbed, distributed, metabolized, and excreted, potentially leading to differences in efficacy and toxicity profiles [1].
What are the regulatory considerations for Onivyde?
Onivyde has received regulatory approval from agencies such as the U.S. Food and Drug Administration (FDA) for its specific indications [1]. The regulatory pathway involves rigorous review of clinical trial data to establish safety and efficacy.
Can biosimilars be developed for Onivyde?
As a complex formulation, the development and approval of biosimilars for liposomal drugs like Onivyde can be more intricate than for simpler small-molecule drugs. The patent landscape and the complexity of the manufacturing process play a significant role in the potential for biosimilar entry [2].
What are patient concerns regarding Onivyde treatment?
Patients often have concerns about the side effects of chemotherapy, including diarrhea, nausea, and fatigue, which are associated with Onivyde [1]. Understanding the management strategies for these side effects and the potential benefits in terms of disease control are key considerations for patients.
*
**Sources:
[1] Ipsen Biopharmaceuticals. Onivyde Prescribing Information.
[2] DrugPatentWatch.com.